ARCHIVES

Phase III Trial of Alimta, Avastin Combination Fails Endpoint to Improve Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 9 | September 28, 2012

Download PDF Visit The Full Archive

Related Articles

Centers Form Big Ten Research Consortium with Access to Over 30,000 New Patients a Year

May 31, 2013

Oncology ManagementL AOR earns $30 Million, PRN Earns $29.8 Million

March 5, 1999

Pharmacia Says SU5416 Doesn’t Benefit Colorectal Cancer Patients, Closes Trial.

March 1, 2002

Competition For Center Grants Higher In FY95, Kimes Tells BSC

November 25, 1994

Talbot, Schein Ask Weickar for 41.3 Billion for NCI

May 6, 1983

Chemo+Radiation Preserves Voice, RTOG Study Finds

December 26, 2003